학술논문
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Document Type
article
Author
Sattui, Sebastian Eduardo; Liew, Jean W; Kennedy, Kevin; Sirotich, Emily; Putman, Michael; Moni, Tarin T; Akpabio, Akpabio; Alpízar-Rodríguez, Deshiré; Berenbaum, Francis; Bulina, Inita; Conway, Richard; Singh, Aman Dev; Duff, Eimear; Durrant, Karen L; Gheita, Tamer A; Hill, Catherine L; Howard, Richard A; Hoyer, Bimba F; Hsieh, Evelyn; Kibbi, Lina El; Kilian, Adam; Kim, Alfred Hyoungju; Liew, David FL; Lo, Chieh; Miller, Bruce; Mingolla, Serena; Nudel, Michal; Palmerlee, Candace A; Singh, Jasvinder A; Singh, Namrata; Ugarte-Gil, Manuel Francisco; Wallace, John; Young, Kristen J; Bhana, Suleman; Costello, Wendy; Grainger, Rebecca; Machado, Pedro M; Robinson, Philip C; Sufka, Paul; Wallace, Zachary S; Yazdany, Jinoos; Harrison, Carly; Larché, Maggie; Levine, Mitchell; Foster, Gary; Thabane, Lehana; Rider, Lisa G; Hausmann, Jonathan S; Simard, Julia F; Sparks, Jeffrey A
Source
RMD Open. 7(3)
Subject
Language
Abstract
BackgroundWe describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.MethodsFrom 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.ResultsWe analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.ConclusionAmong adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.